---
title: "Semnur Pharmaceuticals (SMNR) news: delisting and offering"
url: "https://aibio.space/companies/semnur-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SMNR delisting, offering and merger news: Nasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC. Semnur Pharmaceuticals Inc."
---

SMNR Semnur Pharmaceuticals Inc. OTC · United States

# Semnur Pharmaceuticals (SMNR) news SMNR delisting, offering and merger news

Financings · 2026-07-07

## [Semnur signs binding term sheet for a $100 million investment from iHolding](https://aibio.space/news/semnur-signs-binding-term-sheet-100-million-investment-iholding/)

Semnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.

## Latest Semnur Pharmaceuticals news

1. 2026-04-20 Distress [Semnur terminates two share purchase agreements tied to its 2025 merger](https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/) Semnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.
2. 2025-08-14 Distress [Denali Capital Acquisition Corp. (now Semnur Pharmaceuticals) delays June 10-Q](https://aibio.space/news/denali-capital-acquisition-corp-now-semnur-pharmaceuticals-delays-june/) Denali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.
3. 2025-07-11 Mergers [Denali Capital (now Semnur Pharmaceuticals) extends SPAC deadline to August 11, 2025](https://aibio.space/news/denali-capital-now-semnur-pharmaceuticals-extends-spac-deadline-august/) Denali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.
4. 2025-04-09 Listings [Nasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC](https://aibio.space/news/nasdaq-moves-delist-denali-capital-now-semnur-pharmaceuticals-semnur/) Nasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.

## Semnur Pharmaceuticals at a glance

- **Ticker**: SMNR

- **Listing**: OTC

- **Country**: United States

- **Cash, Jun 30, 2026**: $39,000

### Related companies

- [Lyra Therapeutics](https://aibio.space/companies/lyra-therapeutics/) OTC: LYRA
- [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NASDAQ: NEUP
- [Eli Lilly](https://aibio.space/companies/eli-lilly/) NYSE: LLY
- [Avalyn Pharma](https://aibio.space/companies/avalyn-pharma/) NASDAQ: AVLN
- [Structure Therapeutics](https://aibio.space/companies/structure-therapeutics/) NASDAQ: GPCR
- [NanoViricides](https://aibio.space/companies/nanoviricides/) AMEX: NNVC
- [MacroGenics](https://aibio.space/companies/macrogenics/) NASDAQ: MGNX
- [Clene](https://aibio.space/companies/clene/) NASDAQ: CLNN

### Also on OTC

- [Zivo Bioscience](https://aibio.space/companies/zivo-bioscience/) ZIVO
- [Windtree Therapeutics](https://aibio.space/companies/windtree-therapeutics/) WINT
- [GELSTAT CORP](https://aibio.space/companies/gelstat/) GSAC
- [Halberd](https://aibio.space/companies/halberd/) HALB
- [Carisma Therapeutics](https://aibio.space/companies/carisma-therapeutics/) CARM
- [MabCure](https://aibio.space/companies/mabcure/) MBCI

## Semnur Pharmaceuticals annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$2.5 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) |
| Net income (loss) | [-$160.4 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) | [-$4.7 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) |
| Cash from operations | [-$5.9 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) | [-$4.9 million](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) |
| Cash and equivalents | [$20,000](https://www.sec.gov/Archives/edgar/data/1913577/000119312526342594/) | [$12,000](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $39,000.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Semnur Pharmaceuticals

Was Semnur Pharmaceuticals delisted?

Our latest story on this, dated Apr 9, 2025: "Nasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-moves-delist-denali-capital-now-semnur-pharmaceuticals-semnur/).

Has Semnur Pharmaceuticals raised money recently?

Our latest story on this, dated Apr 20, 2026: "Semnur terminates two share purchase agreements tied to its 2025 merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/).

Is Semnur Pharmaceuticals involved in a merger or acquisition?

Our latest story on this, dated Apr 20, 2026: "Semnur terminates two share purchase agreements tied to its 2025 merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/semnur-terminates-two-share-purchase-agreements-tied-2025-merger/).

What is the ticker symbol of Semnur Pharmaceuticals?

Semnur Pharmaceuticals Inc. trades under the ticker SMNR on OTC.

Where is Semnur Pharmaceuticals listed?

Semnur Pharmaceuticals Inc. is listed on OTC.

What is the SEC CIK of Semnur Pharmaceuticals?

The SEC Central Index Key (CIK) for Semnur Pharmaceuticals Inc. is 1913577. Its filings are on SEC EDGAR.

How many shares does Semnur Pharmaceuticals have outstanding?

230,209,142 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10.

Which country or territory is Semnur Pharmaceuticals listed under?

Our directory records Semnur Pharmaceuticals Inc. under United States.

What does Semnur Pharmaceuticals do?

Our directory classifies Semnur Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Semnur Pharmaceuticals?

The ISIN recorded for Semnur Pharmaceuticals Inc. is US81686G1058.

Does aibio.space cover Semnur Pharmaceuticals?

aibio.space lists Semnur Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Semnur Pharmaceuticals incorporated?

SEC records list its state or country of incorporation as DE.

Is Semnur Pharmaceuticals profitable?

Semnur Pharmaceuticals Inc. reported a net loss of $160.4 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.

How much does Semnur Pharmaceuticals spend on research and development?

$2.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Semnur Pharmaceuticals have?

$39,000 in cash at Jun 30, 2026, per its 10-Q.

## Investor discussion: Semnur Pharmaceuticals

Members talk about Semnur Pharmaceuticals (SMNR). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Semnur Pharmaceuticals, newest first. Each line links the filing it comes from.

1. 2026-07-07 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312526297085/smnr-ex99_1.htm)
2. 2026-04-23 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312526173690/smnr-20260420.htm)
3. 2025-11-12 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312525277536/smnr-20250930.htm)
4. 2025-10-21 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312525245178/d63562ds1.htm)
5. 2025-09-26 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312525220455/d68253dex991.htm)
6. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025076842/ea0253421-nt10q_denali.htm)
7. 2025-07-14 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000135445725000656/xslF25X02/primary_doc.xml)
8. 2025-07-11 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025063308/ea0248712-8k425_denali.htm)
9. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025044260/ea0242266-nt10q_denali.htm)
10. 2025-04-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/ea0237665-8k425_denali.htm)
11. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025026468/ea0236363-nt10k_denali.htm)
12. 2025-03-12 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390025022861/ea0234000-8k425_denalicap.htm)
13. 2024-11-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000121390024098446/ea0221221-nt10q_denali.htm)
14. 2024-11-06 Mergers Filed documents for a merger or acquisition. SEC Form S-4. [Source](https://www.sec.gov/Archives/edgar/data/1913577/000119312524251843/d887184ds4.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:SMNR on TradingView](https://www.tradingview.com/symbols/OTC-SMNR/).

## SEC filings and registration

- **SEC name**: Semnur Pharmaceuticals, Inc.

- **CIK**: 1913577

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: SMNR (OTC), SMNRW (OTC)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

- **Business address**: 960 SAN ANTONIO ROAD, PALO ALTO, CA, 94303

- **Phone**: (650) 516-4310

- **Shares outstanding**: 230,209,142 as of 2026-08-10 (10-Q filed 2026-08-10)

- **Former names**: Denali Capital Acquisition Corp.

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1913577/000119312526342594/smnr-20260630.htm) filed 2026-08-10
- [8-K](https://www.sec.gov/Archives/edgar/data/1913577/000119312526297085/smnr-20260703.htm) filed 2026-07-07
- [8-K](https://www.sec.gov/Archives/edgar/data/1913577/000119312526283007/smnr-20260625.htm) filed 2026-06-25
- [10-Q](https://www.sec.gov/Archives/edgar/data/1913577/000119312526221896/smnr-20260331.htm) filed 2026-05-13
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1913577/000119312526197655/d79397ddef14a.htm) filed 2026-04-30
- [8-K](https://www.sec.gov/Archives/edgar/data/1913577/000119312526173690/smnr-20260420.htm) filed 2026-04-23
- [8-K](https://www.sec.gov/Archives/edgar/data/1913577/000119312526110816/smnr-20260313.htm) filed 2026-03-17
- [10-K](https://www.sec.gov/Archives/edgar/data/1913577/000119312526082642/smnr-20251231.htm) filed 2026-02-27

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001913577), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Semnur Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker SMNR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Semnur Pharmaceuticals Inc.

- **Ticker**: SMNR

- **Listing**: OTC

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US81686G1058

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-SMNR/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/semnur-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Semnur Pharmaceuticals (SMNR) news: delisting and offering", 2026-10-31, https://aibio.space/companies/semnur-pharmaceuticals/